Mini Bone Block Distraction Subtalar Arthrodesis (SAMBB) in the Management of Acquired Adult Flatfoot with Subtalar Arthritis: A Modification to the Grice-Green Procedure.
Mosca M, Caravelli S, Vannini F, Pungetti C, Catanese G, Massimi S, Fuiano M, Faldini C, Giannini S.
Joints. 2019 Dec 13;7(2):64-70. doi: 10.1055/s-0039-3400452. eCollection 2019 Jun.
PMID:31879733
Grice-Green procedure for severe hindfoot valgus in ambulatory patients with cerebral palsy.
Leidinger B, Heyse TJ, Fuchs-Winkelmann S, Paletta JR, Roedl R.
Impact of Subtalar Distraction Arthrodesis on Ankle Joint: Radiological Insights from Modified Grice-Green Procedure.
Artioli E, Mazzotti A, Cassanelli E, Langone L, Astolfi M, Abdi P, Zielli SO, Arceri A, Faldini C.
Life (Basel). 2024 May 28;14(6):692. doi: 10.3390/life14060692.
PMID:38929675
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group.
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
PMID:34000257
Complications of the Grice-Green operation.
Bacardi BE, Rubin SZ, Turf RM.
J Foot Surg. 1989 Jul-Aug;28(4):325-32.
PMID:2794365
[Extra-articular arthroereisis according to Grice/Green versus calcaneal lengthening according to Evans: retrospective comparison for therapy of neurogenic pes planovalgus].
Waizy H, Plaass C, Brandt M, Herold D, Stukenborg-Colsman C, Windhagen H, Claassen L.
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium.
Mol Autism. 2017 May 22;8:21. doi: 10.1186/s13229-017-0137-9. eCollection 2017.
PMID:28540026
[The Grice-Green subtalar arthrodesis using a fibular bone graft--follow-up of 92 patients].
Bollmann C, Franz A, Raabe J.
Z Orthop Unfall. 2015 Feb;153(1):93-8. doi: 10.1055/s-0034-1396245. Epub 2015 Feb 27.
PMID:25723587
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.